Measures associated with how well individuals can modulate their backward walking speed could be used as a screening tool for mobility and cognition problems in people with multiple sclerosis (MS), according to a study by Michigan researchers. A diminished ability to alter walking speed on demand correlated with worse…
walking speed
An extended-release formulation of amantadine, ADS-5102 was significantly more effective than a placebo at increasing walking speed in multiple sclerosis (MS) patients who had difficulty with this, particularly younger patients with a shorter disease course, the INROADS Phase 3 trial demonstrated. Further clinical work on this investigative…
High-dose biotin aided walking speed in people with progressive multiple sclerosis after 12 to 15 months as an add-on treatment, an analysis of placebo-controlled clinical trials shows. However, the therapy failed to improve other measures of disability, and was associated with inaccurate lab test results caused by high levels…
MD1003, MedDay Pharmaceuticals’ high-dose biotin therapy, failed to significantly improve functional ability or walking speed in people with non-active progressive multiple sclerosis (MS), according to data from a Phase 3 clinical trial. Besides failing to meet the trial’s goals, the therapy was associated with inaccurate results in…
Columns
MS News That Caught My Eye Last Week: Mayzent, Hookworm Therapy, Walking and Falling, ADS-5102
NICE Does Not Favor Adding Mayzent to NHS England for Active SPMS Currently, the only disease-modifying therapy approved for use in the National Health Service is Betaferon (interferon beta-1b). That’s a 20-year-old treatment considered to be one of the least effective of the DMTs. NICE concedes that clinical trials…
A Phase 3 trial testing ADS-5102 (amantadine) extended release capsules in all types of multiple sclerosis (MS) is enrolling participants to determine whether the oral therapy can improve walking speed. A total of 570 adults with MS, ages 18 to 70 years, who have difficulty walking will be…
Results from a Phase 2 proof-of-concept study of ADS-5102 (amantadine HCl), showing that multiple sclerosis patients given the extended-release oral treatment improved their walking speed, will be presented at ACTRIMS 2017 this week. Findings in the poster, “A Phase 2 Study of ADS-5102 (amantadine hydrochloride) Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment,”…
Despite recent studies showing that treatment with Ampyra (Fampyra in Europe; fampridine) improves both walking speed and ability, and offers psychological benefits to patients with multiple sclerosis (MS), the Scottish Medicines Consortium (SMC) recently decided to not recommend the drug for use on the National Health Service (NHS) in Scotland.
A pilot study exploring the antioxidant lipoic acid in patients with secondary progressive multiple sclerosis (SPMS) demonstrated that treatment for two years reduced the speed of brain tissue loss and improved the patients’ walking speed. The surprising finding was presented during the “New directions in progressive MS research”…